KRAS mutation: from undruggable to druggable in cancer
L Huang, Z Guo, F Wang, L Fu - Signal transduction and targeted …, 2021 - nature.com
Cancer is the leading cause of death worldwide, and its treatment and outcomes have been
dramatically revolutionised by targeted therapies. As the most frequently mutated oncogene …
dramatically revolutionised by targeted therapies. As the most frequently mutated oncogene …
Mechanisms driving the immunoregulatory function of cancer cells
A van Weverwijk, KE de Visser - Nature Reviews Cancer, 2023 - nature.com
Tumours display an astonishing variation in the spatial distribution, composition and
activation state of immune cells, which impacts their progression and response to …
activation state of immune cells, which impacts their progression and response to …
Mechanisms regulating PD-L1 expression in cancers and associated opportunities for novel small-molecule therapeutics
Antagonistic antibodies targeting the inhibitory immune-checkpoint receptor PD-1 or its
ligand PD-L1 are used to treat a wide range of cancer types and can substantially improve …
ligand PD-L1 are used to treat a wide range of cancer types and can substantially improve …
[HTML][HTML] Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry
Abstract Background Anti-PD1/PD-L1 directed immune checkpoint inhibitors (ICI) are widely
used to treat patients with advanced non-small-cell lung cancer (NSCLC). The activity of ICI …
used to treat patients with advanced non-small-cell lung cancer (NSCLC). The activity of ICI …
Immune modulatory effects of oncogenic KRAS in cancer
Oncogenic KRAS mutations are the most frequent mutations in human cancer, but most
difficult to target. While sustained proliferation caused by oncogenic KRAS-downstream …
difficult to target. While sustained proliferation caused by oncogenic KRAS-downstream …
The lung microenvironment: an important regulator of tumour growth and metastasis
NK Altorki, GJ Markowitz, D Gao, JL Port… - Nature Reviews …, 2019 - nature.com
Lung cancer is a major global health problem, as it is the leading cause of cancer-related
deaths worldwide. Major advances in the identification of key mutational alterations have led …
deaths worldwide. Major advances in the identification of key mutational alterations have led …
Regulation and function of the PD-L1 checkpoint
Expression of programmed death-ligand 1 (PD-L1) is frequently observed in human
cancers. Binding of PD-L1 to its receptor PD-1 on activated T cells inhibits anti-tumor …
cancers. Binding of PD-L1 to its receptor PD-1 on activated T cells inhibits anti-tumor …
Roles of PD-1/PD-L1 pathway: signaling, cancer, and beyond
L Ai, A Xu, J Xu - Regulation of Cancer Immune Checkpoints: Molecular …, 2020 - Springer
Immunotherapies that target PD-1/PD-L1 axis have shown unprecedented success in a wide
variety of human cancers. PD-1 is one of the key coinhibitory receptors expressed on T cells …
variety of human cancers. PD-1 is one of the key coinhibitory receptors expressed on T cells …
[HTML][HTML] The superior efficacy of anti-PD-1/PD-L1 immunotherapy in KRAS-mutant non-small cell lung cancer that correlates with an inflammatory phenotype and …
C Liu, S Zheng, R Jin, X Wang, F Wang, R Zang, H Xu… - Cancer letters, 2020 - Elsevier
Immune checkpoint inhibitors against PD-1/PD-L1 yield improved survival rates of KRAS-
mutant NSCLC patients, who conferred a poor prognosis without effective targeted therapy …
mutant NSCLC patients, who conferred a poor prognosis without effective targeted therapy …
Luteolin and its derivative apigenin suppress the inducible PD-L1 expression to improve anti-tumor immunity in KRAS-mutant lung cancer
ZB Jiang, WJ Wang, C Xu, YJ Xie, XR Wang, YZ Zhang… - Cancer letters, 2021 - Elsevier
Upregulated expression of immune checkpoint molecules correlates with exhausted
phenotype and impaired function of cytotoxic T cells to evade host immunity. By disrupting …
phenotype and impaired function of cytotoxic T cells to evade host immunity. By disrupting …